| Trial ID: | L7382 |
| Source ID: | NCT05429554
|
| Associated Drug: |
Vildagliptin
|
| Title: |
The Effect of Metformin and DPP4 Inhibitors on Cognition and Cardiovascular Protection in Type 2 Diabetic Patients
|
| Acronym: |
|
| Status: |
UNKNOWN
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Type 2 Diabetes Mellitus
|
| Interventions: |
DRUG: Vildagliptin
|
| Outcome Measures: |
Primary: improve the neurodegeneration and cardiovascular effect in diabetic patients, improve the cognition and cardiovascular effect in type 2 diabetic patients, September 2022 |
|
| Sponsor/Collaborators: |
Sponsor: MTI University | Collaborators: National Institute of Diabetes and Endocrinology, Egypt
|
| Gender: |
ALL
|
| Age: |
ADULT
|
| Phases: |
|
| Enrollment: |
60
|
| Study Type: |
OBSERVATIONAL
|
| Study Designs: |
Observational Model: |Time Perspective: p
|
| Start Date: |
2022-06
|
| Completion Date: |
2022-09
|
| Results First Posted: |
|
| Last Update Posted: |
2022-06-23
|
| Locations: |
National Institute of diabetes and endocrinology, Cairo, Al Kasr Al Aini, Egypt
|
| URL: |
https://clinicaltrials.gov/show/NCT05429554
|
